Abstract
Heart rate lowering has an important role in the treatment of coronary artery disease. Lower heart rates extend diastolic filling, facilitating improved myocardial perfusion and reduced myocardial oxygen demand. This has traditionally been achieved with beta-blockers or calcium-channel blockers. Unfortunately both these classes of drugs have sideeffects in a significant minority of patients. The recent development of ivabradine, which acts specifically on the sinoatrial node, offers promise in achieving heart rate reduction without major side effects. Ivabradine selectively and specifically inhibits the If channel which is integral to the generation of the pacemaker current in the sinoatrial node. Initial studies utilising ivabradine show improvements in exercise tolerance and time to developing ischaemia during exercise in patients with chronic stable angina. Ivabradine has no negative inotropic effects and does not appear to have any major side-effects. It has been shown to have similar antianginal and anti-ischaemic effects to atenolol and amlodipine. Animal studies have suggested that ivabradine may have beneficial effects in chronic heart failure leading to improvements in left ventricular function. In humans with stable coronary artery disease, left ventricular dysfunction and heart rates of 70bpm or more, ivabradine appears to reduce rates of revascularisation and hospitalisation for myocardial infarction.
Keywords: Funny channel, Ivabradine, chronic stable angina, heart rate lowering
Current Drug Therapy
Title: Sinus Node If Channel Inhibition – A New Therapeutic Approach to Heart Rate Lowering
Volume: 4 Issue: 1
Author(s): Anne E. Scott, Kirsten Kruszewski and Stephen J. Leslie
Affiliation:
Keywords: Funny channel, Ivabradine, chronic stable angina, heart rate lowering
Abstract: Heart rate lowering has an important role in the treatment of coronary artery disease. Lower heart rates extend diastolic filling, facilitating improved myocardial perfusion and reduced myocardial oxygen demand. This has traditionally been achieved with beta-blockers or calcium-channel blockers. Unfortunately both these classes of drugs have sideeffects in a significant minority of patients. The recent development of ivabradine, which acts specifically on the sinoatrial node, offers promise in achieving heart rate reduction without major side effects. Ivabradine selectively and specifically inhibits the If channel which is integral to the generation of the pacemaker current in the sinoatrial node. Initial studies utilising ivabradine show improvements in exercise tolerance and time to developing ischaemia during exercise in patients with chronic stable angina. Ivabradine has no negative inotropic effects and does not appear to have any major side-effects. It has been shown to have similar antianginal and anti-ischaemic effects to atenolol and amlodipine. Animal studies have suggested that ivabradine may have beneficial effects in chronic heart failure leading to improvements in left ventricular function. In humans with stable coronary artery disease, left ventricular dysfunction and heart rates of 70bpm or more, ivabradine appears to reduce rates of revascularisation and hospitalisation for myocardial infarction.
Export Options
About this article
Cite this article as:
Scott E. Anne, Kruszewski Kirsten and Leslie J. Stephen, Sinus Node If Channel Inhibition – A New Therapeutic Approach to Heart Rate Lowering, Current Drug Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488509787081859
DOI https://dx.doi.org/10.2174/157488509787081859 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Capillary Degeneration and Right Ventricular Remodeling Due to Hypoxic Stress with Sugen5416
Current Vascular Pharmacology Is Combined Angiotensin-converting Enzyme Inhibition and Angiotensin Receptor Blockade Associated with Increased Risk of Cardiovascular Death in Hemodialysis Patients?
Current Hypertension Reviews The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology Editorial(Angiotensin II Receptor Research)
Current Pharmaceutical Design Angiotensin II-Vasopressin Interactions in The Regulation of Cardiovascular Functions. Evidence for an Impaired Hormonal Sympathetic Reflex in Hypertension and Congestive Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
Current Pharmaceutical Design The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Catheter-directed Thrombolysis <i>versus</i> Systemic Anticoagulation for Submassive Pulmonary Embolism: A Meta-Analysis
Current Cardiology Reviews ENaC Modulators and Renal Disease
Current Molecular Pharmacology 1h Post-load Blood Glucose in the Identification of Proatherogenic Cardiometabolic Profile in Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews Pharmacy and Exercise as Complimentary Partners for Successful Cardiovascular Ageing
Current Vascular Pharmacology Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine New Targets for Therapy in Polyglutamine (polyQ) Expansion Diseases
Current Drug Therapy Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design Analogy of Cardiac and Renal Complications in Essential Hypertension and Aged SHR or L-NAME/SHR
Medicinal Chemistry Cardiomyocyte-Specific TβR2 Knockout Mice are More Susceptible to Cardiac Hypertrophy Induced by Adrenergic Agonist Stimulation
Current Molecular Medicine